Cargando…
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Surgery is the standard of care for patients with operable non-small cell lung cancer (NSCLC). However, as a single modality, surgery for early stage or locally advanced NSCLC remains associated with high rates of local and distant recurrence. The addition of neoadjuvant or adjuvant chemotherapy has...
Autores principales: | Huynh, Caroline, Walsh, Logan A., Spicer, Jonathan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867741/ https://www.ncbi.nlm.nih.gov/pubmed/33569337 http://dx.doi.org/10.21037/tlcr-20-509 |
Ejemplares similares
-
Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021) -
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
por: Pradhan, Monika, et al.
Publicado: (2021) -
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021) -
Mediastinal staging for non-small cell lung cancer
por: Leiro-Fernández, Virginia, et al.
Publicado: (2021) -
Induction treatment in patients with stage III non-small cell lung cancer
por: Palmero, Ramón, et al.
Publicado: (2021)